Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344464 | 0.83 | PIK3CA (0.63) | PIK3CAKCNK3NPSR1PTGS1 | |
| SCHEMBL23344471 | 0.79 | PIK3CA (0.79) | PIK3CAMEN1KMT2A | |
| SCHEMBL23344505 | 0.75 | PIK3CA (0.86) | PIK3CAMEN1KMT2A | |
| SCHEMBL23344439 | 0.73 | PIK3CA (0.76) | PIK3CAMEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL23344479 | 0.71 | PIK3CA (0.71) | PIK3CAMEN1KMT2AL3MBTL1 | |
| SCHEMBL21311188 | 0.66 | HTT (0.62) | RXFP1MEN1KMT2AKCNK3KCNK9 | |
| SCHEMBL23326384 | 0.65 | BRAF (0.54) | RXFP1MEN1KMT2AKCNK3KCNK9 | |
| SCHEMBL26405724 | 0.64 | SORT1 (0.54) | MEN1KMT2AABL1SRCKCNK3 | |
| SCHEMBL23326225 | 0.64 | PIK3CA (0.53) | PIK3CAMEN1KMT2A | |
| SCHEMBL23344477 | 0.63 | MEN1 (0.53) | PIK3CAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | CITY OF HOPE (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | PDXK, DPYD, PNPO | PIK3CA 1262/4885RXFP1 4490/4885MEN1 4106/4885 |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | PDXK, DPYD, PNPO | PIK3CA 1262/4885RXFP1 4490/4885MEN1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.